EIGHTH INTERNATIONAL CONFERENCE 
ON BIPOLAR DISORDER


June 25-27, 2009

David L. Lawrence Convention Center
Pittsburgh, Pennsylvania


Home | Welcome & Overview | MultiMedia Presentations | Links | ICBD Archives | UPMC Psychiatry | Contact Us

Biographical Sketches

COURSE DIRECTORS

Ellen Frank, PhD
Distinguished Professor of Psychiatry and Professor of Psychology
University of Pittsburgh School of Medicine
Director, Depression and Manic Depression Prevention Program
Western Psychiatric Institute and Clinic, Pittsburgh, PA

Ellen Frank is Distinguished Professor of Psychiatry and Professor of Psychology at the University of Pittsburgh School of Medicine and director of the Depression and Manic Depression Prevention program at Western Psychiatric Institute and Clinic.

Dr. Frank and her colleagues developed a new psychotherapy—interpersonal and social rhythm therapy—for the treatment of manic depressive illness under a MERIT award from the National Institute of Mental Health (NIMH). She recently completed an NIMH-sponsored study of women with recurrent depression in which she examined how psychobiology, life stress, and different “doses” of psychotherapy interact to increase or decrease vulnerability to new episodes of depression. In addition, Dr. Frank is completing a joint project with researchers at the University of Pisa, Italy, aimed at achieving a better understanding of the clinical importance of subsyndromal mood, anxiety and eating disorders—that is, when the symptoms are not severe enough for diagnosis as a clinically recognized syndrome.

An expert in mood disorders and their treatment, Dr. Frank was Chair of the Food and Drug Administration Psychopharmacologic Drugs Advisory Panel. She also is a former member of the National Advisory Mental Health Council. She currently serves on the Mood Disorders Workgroup of the American Psychiatric Association Task Force on DSM-V. Dr. Frank is an honorary fellow of the American Psychiatric Association. In 1999 she was elected to the National Academy of Sciences Institute of Medicine.

A graduate of Vassar College, Dr. Frank earned a master’s degree in English at Carnegie Mellon University and a doctorate in psychology at the University of Pittsburgh.


Samuel Gershon, MD
Vice Chairman, Academic Affairs, Department of Psychiatry, University of Miami, Miami, Florida
Emeritus Professor of Psychiatry, University of Pittsburgh School of Medicine
Western Psychiatric Institute and Clinic, Pittsburgh, PA

Dr. Samuel Gershon joined the faculty at the University of Pittsburgh in April 1988, as Associate Vice Chancellor for Research in the Health Sciences, and Associate Research Director for the Neurosciences in the Department of Psychiatry. He stepped down from this position in 1995 and assumed the position of Chairman of the Institutional Review Board, University of Pittsburgh. Prior to his tenure with the University of Pittsburgh, Dr. Gershon was Director of the Neuropsychopharmacology Research Unit at New York University for 16 years. He then assumed the position of Professor and Chairman of the Department of Psychiatry at Wayne State University and was also the Director of the Lafayette Clinic. He was a longtime recipient of NIH Research Support during his years as an investigator.

Dr. Gershon’s career as a psychiatrist and investigator spans more than 50 years. During this time he has published more than 600 writings and has won several prestigious awards including, among others, the Pfizer Scholarship for Medical Research Overseas, the American Psychiatric Association’s Rush Gold Medal Award, the 6th ICBD Mogens Schou Award for Distinguished Service, and in 2008 the CINP Pioneer Award in Neuropsychopharmacology. His area of specific interest and work encompasses psychopharmacological interest in various psychiatric areas. He is currently the Co-Editor of Bipolar Disorders – An International Journal of Psychiatry and Neurosciences and has been since its inception in 1998. He is also a founding Councilor of the International Society for Bipolar Disorders and served as President from 2001-2005. He is currently Vice Chairman for Academic Affairs at the Department of Psychiatry, University of Miami.


David J. Kupfer, MD
Thomas Detre Professor and Chairman
Department of Psychiatry
University of Pittsburgh School of Medicine
Medical Director and Director of Research
Western Psychiatric Institute and Clinic, Pittsburgh, PA

David J. Kupfer, M.D., Thomas Detre Professor and Chairman of the Department of Psychiatry and Professor of Neuroscience at the University of Pittsburgh School of Medicine, received his bachelor’s (magna cum laude) and M.D. degrees from Yale University. Following completion of an internship, Dr. Kupfer continued his postgraduate clinical and research training at the Yale New Haven Hospital and at the National Institute of Mental Health (NIMH). In 1970, he was appointed an assistant professor of psychiatry at Yale University School of Medicine. Dr. Kupfer joined the faculty at the University of Pittsburgh in 1973 as an associate professor of psychiatry and director of research and research training at Western Psychiatric Institute and Clinic. He was promoted to professor of psychiatry in 1975 and became chairman of the department in 1983. As Thomas Detre Professor and Chairman of the Department of Psychiatry and Director of Research at WPIC, he oversees the coordination and expansion of investigations among the department’s 200 faculty. He has promoted widespread collaborations between clinical investigators in psychiatry and those in more basic neurosciences. Under Dr. Kupfer’s direction, WPIC has become one of the nation’s preeminent university-based psychiatric centers as evidenced by the quality and number of publications as well as the amount of peer-reviewed federal funding for mental health research. He has written more than 972 articles, books, and book chapters that examine treatment in recurrent depression, the causes of depression, and the relationship between biomarkers and depression.

In recognition of his contributions to the field, Dr. Kupfer has been the recipient of numerous awards and honors including the A.E. Bennett Research Award in Clinical Science (1975), the Anna-Monika Foundation Prize (1977), the Daniel H. Efron Award (1979), the Twenty-Sixth Annual Award of the Institute of Pennsylvania Hospital in Memory of Edward A. Strecker, M.D. (1989), the William R. McAlpin, Jr, Research Achievement Award (1990), the 1993 American Psychiatric Association Award for Research in Psychiatry, the First Isaac Ray Decade of Excellence Award (1994), the Twelfth Annual Edward J. Sachar Award (1996), the 1996 Gerald Klerman Lifetime Research Award (jointly with Dr. Ellen Frank), the Institute of Medicine’s 1998 Rhoda and Bernard Sarnat International Prize in Mental Health, and the American Psychopathological Association’s 1999 Joseph Zubin Award (jointly with Dr. Ellen Frank). He was elected to the Institute of Medicine of the National Academy of Sciences in 1990. Dr. Kupfer is the Founding President of the International Society of Bipolar Disorders. Dr. Kupfer chairs the Task Force for DSM-V.
 


Michael E. Thase, MD
Professor of Psychiatry, University of Pennsylvania School of Medicine
Philadelphia Veterans Affairs Medical Center, Philadelphia, PA

Michael E. Thase, M.D., joined the faculty of the University of Pennsylvania School of Medicine in January, 2007 as Professor of Psychiatry after more than 27 years at the University of Pittsburgh Medical Center and the Western Psychiatric Institute and Clinic. Dr. Thase’s research focuses on the assessment and treatment of mood disorders, including studies of the differential therapeutics of both depression and bipolar affective disorder. A 1979 graduate of the Ohio State University College of Medicine, Dr. Thase is a Distinguished Fellow of the American Psychiatric Association, a Founding Fellow of the Academy of Cognitive Therapy, a member of the Board of Directors of the American Society of Clinical Psychopharmacology, and Vice Chairman of the Scientific Advisory Board of the National Depression and Bipolar Support Alliance. Dr. Thase has been elected to the membership of the American College of Psychiatrists and the American College of Neuropsychopharmacology. Dr. Thase has authored or co-authored more than 500 scientific articles and book chapters, as well as 15 books.

Faculty


Ole A. Andreassen, MD, PhD
Professor of Psychiatry, University of Oslo, Faculty of Medicine
Oslo University Hospital, Ullevål, Oslo, Norway

Ole A. Andreassen, M.D., Ph.D., joined the faculty of the University of Oslo in 2005. Dr. Andreassen is the head of the TOP study, and his research focuses on the underlying pathophysiology of bipolar disorder related to brain function and genetic susceptibility, and overlapping phenotypes with schizophrenia. Andreassen graduated from University of Bergen, Faculty of Medicine in 1993, received a PhD in psychopharmacology from the same university in 1996, and was post doc at Harvard Medical School / Massachusetts General Hospital in 1998-2000. Dr. Andreassen is a member of the Norwegian Psychiatric Association, member of the board of directors of the Norwegian Society for Bipolar Disorder, and a member of the Steering Committee of the European ENBREC Network. Dr. Andreassen has authored or co-authored more than 80 scientific articles and 10 book chapters.


Peter C. Ashenden
President, CEO, Depression Bipolar Support Alliance (DBSA), Chicago, IL

Peter Ashenden is a consumer/survivor and the current President/CEO for the Depression Bipolar Support Alliance (DBSA). He formerly held the position of Executive Vice President at DBSA, a position he started in August 2007. He is the former Executive Director of the Mental Health Empowerment Project (MHEP), a position he held for 11 years; he provides training to consumer/survivors and mental health professionals nationally and has been active in starting many self-help groups. He is also a well known Keynote Speaker at many mental health related events throughout the country including a Keynote Speaker at the Alternatives 2004 Conference held in Denver, CO. He is a former Commissioner of the Certification Commission of USPRA formerly IAPSRS. He is currently the Chair-Elect and Executive Committee Member of the Board of USPRA. Peter also serves as a member of the Board of the Verrazano Foundation located in Staten Island, NY is a member of the Board of Mental Health Empowerment Project, and is a former member and Secretary of the Board of the Depression Bipolar Support Alliance. He is a former member of the CARF (the Accreditation Association) Board. He was also a former member of the Board of PEOPLe, Inc., the Mental Health Association of New York State (MHANYS), and the Treasurer for the Peer Accreditation Project of New York State. Additionally, he was an Executive Committee Member and the USPRA representative for the New York Association of Psychiatric Rehabilitation Services (NYAPRS), a position he held for over 12 years.


David A. Axelson, MD
Associate Professor of Psychiatry, University of Pittsburgh School of Medicine
Director of the Child and Adolescent Bipolar Services (CABS)
Western Psychiatric Institute and Clinic, Pittsburgh, PA

David Axelson, M.D. is an Associate Professor of Psychiatry at the University of Pittsburgh School of Medicine and the Director of the Child and Adolescent Bipolar Services (CABS) program at the Western Psychiatric Institute and Clinic. Dr. Axelson received a B.A. in 1987 from Brown University and his M.D. in 1992 from the Duke University School of Medicine. He completed a combined General – Child Psychiatry residency at Western Psychiatric Institute and Clinic in 1997 and a post-doctoral research fellowship in child and adolescent mood disorders at the University of Pittsburgh School of Medicine. Dr. Axelson’s research focuses on the phenomenology, course and treatment of children and adolescents with bipolar spectrum disorders. He received a career development award from the National Institute of Mental Health and is currently a Principal Investigator on two multisite NIMH-funded treatment studies of bipolar youth. He is also a Co-Principal Investigator for studies examining the phenomenology of pediatric bipolar disorder and the longitudinal course of the offspring of bipolar parents. Dr. Axelson is on the Editorial Board of the Journal of the American Academy of Child and Adolescent Psychiatry.


Deanna M. Barch, PhD
Professor of Psychology, Psychiatry and Radiology
Washington University, Saint Louis, MO

Deanna M. Barch, Ph.D. is Professor of Psychology, Psychiatry and Radiology at Washington University in Saint Louis, Missouri. Dr. Barch received her undergraduate degree from Northwestern University, completed her doctorate in Clinical Psychology at the University of Illinois in Champaign-Urbana, and completed an NIMH sponsored postdoctoral fellowship at Western Psychiatric Institute and Clinic at the University of Pittsburgh School of Medicine. Dr. Barch is the Editor-in-Chief of Cognitive, Affective and Behavioral Neuroscience, is on the Editorial Board of Schizophrenia Bulletin, sits on the Adult Psychopathology and Aging NIH review group, and is a member of the MATRICS neurocognition committee. Her research has been funded by the NIMH, the NIA, NARSAD and the Dana Foundation. She is Director of the Conte Center for the Neuroscience of Mental Illness at Washington University in St. Louis, and Principal Investigator of the Washington University Treatment Units Research Network Site. Dr. Barch has authored or co-authored more than 100 articles and book chapters related to cognitive, emotion and brain function in psychotic and mood disorders. She is a frequent lecturer both in the United States and abroad.


Monica Ramirez Basco, PhD
Assistant Professor of Psychology
University of Texas at Arlington, Arlington, TX

Monica Ramirez Basco, a Clinical Psychologist, is an internationally recognized expert in cognitive-behavior therapy and a founding fellow of the Academy of Cognitive Therapy. She has lectured throughout North America as well as in South and Central America and Europe and has been training physicians, psychologists, and other mental health professionals for the past 20 years in cognitive behavioral treatment methods. She is the author of 7 books, numerous book chapters, and research articles.

She completed her doctoral training at the University of Southern California in 1987. After internships at the University of California, San Diego and the San Diego Child Guidance Clinic, she joined the research faculty at U. T. Southwestern Medical Center, Department of Psychiatry. There she conducted research on the assessment and treatment of severe mental disorders with a specialty in bipolar disorder. She also participated in research on the behavioral management of Insulin Dependent Diabetes. In collaboration with other researchers, Dr. Basco has received several research grant awards. In 1992 she received the Young Investigator Research Award for her work on marriage and depression from the Association for the Advancement of Behavior Therapy. With collaborator John Rush, Dr. Basco developed the first cognitive-behaviorally based treatment program for bipolar disorder. Her current research efforts are in disseminating evidenced based psychotherapeutic treatments to community mental health centers and in increasing the durability of cognitive therapy for depression.

Dr. Basco’s books are entitled “Cognitive Behavior Therapy for Bipolar Disorder”(1996, 2005, Guilford Press); “Never Good Enough: How to Use Perfectionism to your Advantage without Letting it Ruin your Life” (1999, Free Press), “Getting Your Life Back: The Complete Guide to Recovery from Depression” (2001, Free Press), “The Bipolar Workbook” (2006, Guilford), “Learning Cognitive Therapy: An Illustrated Guide” (2005, APPI) and Cognitive Behavior Therapy for Severe Mental Disorders (2008, APPI).


Mark S. Bauer, MD
Professor of Psychiatry, Harvard Medical School
Director, Harvard South Shore
Psychiatry Residency Training Program
Center for Organization, Leadership, & Management Research, VA Healthcare System, Boston, MA

Dr. Bauer’s research focus for the last decade has been on developing, testing, and implementing collaborative chronic care models to improve evidence-based treatment delivery for manic-depressive disorder and other serious mental illnesses. He has pioneered the development of self-management skill enhancement methodologies for individuals with bipolar disorder through the portfolio of Life Goals treatments. He has also contributed to research on the nosology, assessment, and treatment of bipolar disorder particularly rapid cycling. Dr. Bauer received his bachelor’s degree from the University of Chicago and medical degree from the University of Pennsylvania. He has also served on the faculty of psychiatry and pharmacology at the University of Pennsylvania and the faculty of psychiatry at Brown University. He is the author of over 100 scientific articles and author or editor of 6 books. He has won awards for excellence in research, teaching, clinical care, and administration. He has been named Distinguished Fellow of the American Psychiatric Association and is a member of the Executive Committee of the Scientific Advisory Board of the Depression and Bipolar Support Alliance.


Carrie E. Bearden, PhD
Associate Professor, Departments of Psychiatry and Biobehavioral Sciences and Psychology
Semel Institute for Neuroscience and Human Behavior
University of California at Los Angeles, Los Angeles, CA

Dr. Carrie Bearden received her Ph.D. in Clinical Psychology from the University of Pennsylvania in 1999. From 2000 to 2001 she received training in adult and pediatric neuropsychology, during her internship at the San Diego VA Medical Center and UCSD Child & Adolescent Psychiatry Services. From 2001 to 2002, Dr. Bearden became a Postdoctoral Fellow under an NIMH Neuroscience Training Grant at the Childrens Hospital of Philadelphia, where she obtained further experience in pediatric cognitive neuroscience. Dr. Bearden’s research aims to understand genetic influences on brain structure in the development of psychosis and mood disorder, using converging methods to study cognition and neuroanatomy in clinical high-risk samples (i.e., adolescents at ultra high-risk for psychosis, relatives of bipolar probands), and in possible highly penetrant ‘genetic subtypes’ of complex neuropsychiatric disorders (i.e., 22q11.2 microdeletions). She joined the faculty at UCLA in 2003, as an Assistant Professor in the Departments of Psychiatry and Biobehavioral Sciences and Psychology. She has received numerous awards and honors, including Young Investigator Awards from the International Congress for Schizophrenia Research and the National Alliance for Research on Schizophrenia and Affective Disorders (NARSAD), and the American College of Neuropsychopharmacology (ACNP), the A.E. Bennett Neuropsychiatric Research Award for Clinical Science in Biological Psychiatry, and the Samuel Gershon Junior Investigator Award from the International Society for Bipolar Disorders. Dr. Bearden has authored or co-authored over 100 scientific articles, book chapters, and published abstracts.


Francesco Benedetti, MD
Head of the Psychiatry and Clinical Neurosciences Research Group
San Raffaele Hospital, Milano, Italy

Francesco Benedetti, MD is Head of the Psychiatry and Clinical Neurosciences research group at the San Raffaele Hospital in Milano, and contract professor of Psychiatry and of General Psychopatology at the University Vita-Salute San Raffaele.

His clinical research group gathers researchers working at the interface between neuroscience and behavioral disorders. Areas of expertise encompass clinical psychobiology, brain imaging, genetics of response to psychiatric treatments, pharmacology, neuropsychology, neurophysiology, and and genetic correlates of psychopathological conditions.

In the last 15 years he and his group have developed clinical chronotherapeutics of mood disorders into a practicable everyday method for the psychiatric ward, particularly focussing on bipolar disorder. They found that the same gene polymorphisms that hinder clinical response to antidepressants affect the response to chronotherapeutics in a similar fashion, and explored the role of genetic polymorphisms affecting both the monoaminergic pathways and the biological clock. At the MRI level, they studied functional and structural correlates and determinants of psychopatological conditions, with a particular emphasis on major psychoses. These multiple approaches provide an important scientific database to document efficacy and mechanisms of action of antidepressant methods, and biological underpinnings of psychiatric illnesses.


Francine M. Benes, MD, PhD
Director, Program in Structural and Molecular Neuroscience, Harvard Brain Tissue Resource Center
Professor of Psychiatry, Harvard Medical School, McLean Hospital, Boston, MA

Dr. Benes is the William P. and Henry B. Text Professor of Psychiatry (Neuroscience) at Harvard Medical School. She received her bachelor’s degree from St. John’s University in New York in 1967 and in 1972 completed a Ph.D. in Cell Biology at the Yale School of Medicine. She received postdoctoral training in single cell neurochemistry at the City of Hope National Medical Center in California and later in the Section of Cell Biology at Yale where she studied the re-cycling of synaptic vesicle membrane in frog neuromuscular junction. In 1975, she began medical training at Yale and after graduating in 1978, completed a residency in psychiatry at McLean Hospital and Harvard Medical School. In the past 20 years, Dr. Benes’ research has been directed at systematically identifying specific ways in which the neural elements related to the glutamate, GABA and dopamine systems are abnormal in the limbic lobe of schizophrenics and bipolars. Currently, the work in her laboratory is focused on the molecular regulation and functional differentiation of the GABA cell phenotype in interneurons in the adult hippocampus in schizophrenia and bipolar disorder.

Dr. Benes directs the Program in Structural and Molecular Neuroscience at McLean Hospital and the Harvard Brain Tissue Resource Center. She has served on the Editorial Boards of 15 different neuroscience and psychiatry journals and the advisory board of several different research organizations. Dr. Benes has been invited to present her research at many international meetings. In 1997, she was invited to present her work at the College de France in Paris and in 1998 at a Nobel Symposium on Schizophrenia at the Karolinska University in Stockholm. She has been the recipient of many different awards and honors, including a MERIT Award from the National Institute of Mental Health, the Lieber Prize for Outstanding Achievement in Schizophrenia Research (National Association for Research in Schizophrenia and Depression; NARSAD), the William Silens Lifetime Achievement in Mentoring Award, the Kempf Fund Award for Research Development in Psychobiological Psychiatry (American Psychiatric Association) and the Lucille and Sidney Malitz Scholar, Dept. Psychiatry, Columbia Presbyterian Medical Center. In 2004, Dr. Benes was elected to the Institute of Medicine of the National Academy of Science.


Michael Berk, MD, PhD
Chair of Psychiatry for Barwon Health and The Geelong Clinic
The University of Melbourne, Melbourne, Australia

Professor Michael Berk is currently appointed to the Chair of Psychiatry for Barwon Health and The Geelong Clinic at The University of Melbourne. He also is an Honorary Professorial Research fellow at the Mental Health Research Institute, and leads the first episode bipolar program at Orygen Youth Health. He has published over 250 papers on a range of topics with his research interests focusing on mood and psychotic disorders, particularly bipolar disorder and depression. He has published 17 self-initiated randomised controlled trials, predominantly in bipolar disorder. These include the first two published randomised trials of the atypical antipsychotics and lamotrigine in bipolar disorder, both of which are now established treatments, the largest trials of verapamil in mania and norethisterone in depression, and three RCT’s of antidepressants in schizophrenia. He is regularly invited as a guest speaker at international meetings. He is the recipient of a number of grants, including a NHMRC CCRE and 3 project grants, a beyondblue grant and three Stanley Medical Research Institute awards, and is the principal investigator on a number of current trials. These include two randomised placebo controlled trials of N-acetyl cysteine in both depression and Bipolar Disorders, which follow up two positive trials of NAC in schizophrenia and bipolar disorder, that have broken new ground in establishing both an entirely novel treatment and implicating a novel mechanism of disease. In 2008, he was awarded the Australasian Society of Psychiatric Research Eli Lilly Oration, the Pathcare Smart Geelong Research and Learning Expo Health and Lifestyle award and the G Force Recruitment Researcher of the year award for this work. A significant body of research was undertaken in South Africa and was often accomplished in poorly funded and supported environments. Since relocating, he has established a new research unit at Barwon Health, which now has 35 researchers engaged in 33 projects, multiple, local national and international collaborations, as well as a clinical Professorial Unit at the Geelong Clinic. He is Chairman of the International Society of Bipolar Disorders, and Vice Chairman of the Australasian Society of Bipolar Disorders. He is a committee member of both the Collegium Internationale Psychopharmacologicum and World Federation of Societies of Biological Psychiatry is a member of a number of international advisory boards. He was the founding editor of The Journal of Depression and Anxiety, and has served as guest editor or is on the editorial board of 12 other journals as well as being a reviewer of 30 journals.


Boris Birmaher, MD
Endowed Chair in Early Onset Bipolar Disease and Professor of Psychiatry
University of Pittsburgh, School of Medicine, Pittsburgh, PA

Boris Birmaher, MD is the Endowed Chair in Early Onset Bipolar Disease and Professor of Psychiatry at the University of Pittsburgh, School of Medicine. He has board certifications in both general psychiatry and child psychiatry. He received his medical degree from Valle University in Cali, Colombia and completed his training in general psychiatry at the Hebrew University, Hadassah Medical Center in Jerusalem, Israel. He received his training in biological psychiatry at the Albert Einstein College of Medicine in New York and training in child psychiatry at Columbia University, New York Psychiatric Institute in New York.

Dr. Birmaher has been involved in clinical work and research in pediatric mood and anxiety disorders for over 25 years. His research interests include areas of phenomenology, course and outcome, etiology, and pharmacology and psychosocial treatments. Among other studies, he is currently involved in several NIMH studies including: 1) “Course and Outcome for Adolescents with Bipolar Illness”, that is aimed at describing the phenomenology, course, and associated factors in children and adolescents with bipolar spectrum disorder; 2) “Children of Bipolar Parents: A High Risk Follow-up Study”, that is aimed at studying the longitudinal psychopathology of children of parents with bipolar disorder compared with children of community controls; and 3) “Longitudinal Assessment of Manic Symptoms” , that is aimed at evaluating the predictive value of early-onset manic symptoms in a large sample of children ages 6-12 years old. Together with Dr. David Axelson, he is the Co-Director of the Child and Adolescent Bipolar Services (CABS) program, a program for the service, teaching and research of bipolar disorder in youth.


Hilary P. Blumberg, MD
Associate Professor of Psychiatry, Diagnostic Radiology and in the Child Study Center
Director, Mood Disorders Research Program
Yale School of Medicine, New Haven, CT

Hilary P. Blumberg, MD, joined the faculty of the Yale School of Medicine in 1998. She was an undergraduate at Harvard University and completed her medical school, psychiatry residency and neuroimaging fellowship training at the New York Hospital-Cornell Medical Center. Dr. Blumberg’s research focuses on the study of genetic and environmental influences on the development of corticolimbic circuitry differences in bipolar disorder for which she employs multi-modal structural and functional neuroimaging methods. Dr. Blumberg is a Fellow of the American Psychiatric Association, Associate Member of the American College of Neuropsychopharmacology and the Society of Biological Psychiatry. She is the recipient of numerous awards including the National Alliance for Research in Schizophrenia and Depression (NARSAD) Gerald L. Klerman Award for Clinical Research. She has authored dozens of scientific articles on neuroimaging findings in bipolar disorder, including her most recent work that demonstrates effects of specific genetic variations, developmental trajectories and structure-function relationships.


David A. Brent, MD
Academic Chief, Child and Adolescent Psychiatry, Western Psychiatric Institute and Clinic
UPMC Endowed Chair in Suicide Studies, and Professor of Psychiatry, Pediatrics and Epidemiology
University of Pittsburgh School of Medicine, Pittsburgh, PA

Dr. Brent is Academic Chief, Child and Adolescent Psychiatry at Western Psychiatric Institute and Clinic. He holds the UPMC Endowed Chair in Suicide Studies, and is Professor of Psychiatry, Pediatrics and Epidemiology, University of Pittsburgh School of Medicine. A graduate of Jefferson Medical College of the Thomas Jefferson University (1974), Dr. Brent trained in pediatrics at the University of Colorado, in general and child psychiatry at Western Psychiatric Institute and Clinic, and completed a master’s degree in psychiatric epidemiology at the University of Pittsburgh School of Public Health. Dr. Brent is a member of the Institute of Medicine of the National Academy of Sciences, and has received many honors and awards including the Blanche F. Ittleson Award for Research in Child and Adolescent Psychiatry (APA), the Beatrice Cummings Mayer Award (AACAP), the Research Award for Research on Mood Disorders and Suicide (AFSP), and the Ruane Prize for Outstanding Achievement in Adolescent Psychiatric Research (NARSAD). He co-founded and now directs Services for Teens at Risk (STAR), a Commonwealth of Pennsylvania-funded program for suicide prevention, education of professionals, and the treatment of at-risk youth and their families. His work in the area of suicide has focused on the epidemiology of adolescent suicide, and has helped to identify the role of mood disorders, substance abuse, family history of suicide, and the role of firearms as risk factors for youth suicide. Consequently, he and colleagues at Western Psychiatric Institute and Clinic have helped to establish the role of cognitive therapy as a treatment for depressed adolescents in two NIMH-funded clinical trials. Dr. Brent has also focused on the familial and genetic aspects of suicide; having found that suicidal behavior clusters in families and has, along with colleagues at New York State Psychiatric Institute, identified mechanisms that may explain how suicidal behavior may be transmitted from parent to child. He has directed an NIMH-funded T32 postdoctoral training grant that has produced more than a dozen career awardees, many of whom have gone on to be leaders in child mental health research. He has published over 150 peer-reviewed articles and 60 book chapters and invited reviews on these subjects.


Joseph R. Calabrese, MD
Bipolar Disorders Research Chair and Professor of Psychiatry
University Hospitals Case Medical Center
Case Western Reserve University School of Medicine, Cleveland, OH

Joseph R. Calabrese, M.D., joined the faculty of Case Western Reserve University School of Medicine in January, 1989 to start the Mood Disorders Program. A 1980 graduate of the Ohio State University College of Medicine, Dr. Calabrese is a Fellow of the American Psychiatric Association and the American College of Neuropsychopharmacology.

Dr. Calabrese also co-directs an NIMH-funded ‘Bipolar Disorders Research Center’, whose projects include research conducted by Bob Findling (Director of Child and Adolescent Psychiatry) whose projects focus on the phenomenology and treatment of juvenile bipolar, research conducted by Martha Sajatovic (Director of Geriatric Psychiatry) whose projects include late life bipolar disorder, Keming Gao (Director, Mood and Anxiety Clinic), and Dave Kemp (Director, Mood and Metabolic Clinic).

The research center is dedicated to the improvement of clinical outcomes in under-served populations of bipolar disorder, including those with bipolar depression, rapid cycling, children and adolescents, adults currently comorbid with anxiety and substance use disorders, legal complications of bipolar disorder, those receiving care within community mental health centres, older adults, and service members within the Ohio National Guard.

Dr. Calabrese has authored more than 300 scientific articles and book chapters, and has received numerous research grants from the NIMH and Federal agencies. His primary scientific focus is the short- and long-term treatment of bipolar disorder, with special emphasis on bipolar depression and the rapid cycling pattern of presentation. Dr. Calabrese was chosen by psychiatry residents to receive the ‘Best Teacher of the Year Award’ in three different years, received the NARSAD Lifetime Achievement Award for his research in bipolar disorder in 2005, Ellis Island Medal of Honor in 2006, and the Gerald L. Klerman Lifetime Achievement Award in 2008.


William T. Carpenter, Jr., MD
Director, Maryland Psychiatric Research Center
Professor of Psychiatry and Pharmacology, University of Maryland School of Medicine, Baltimore, MD

William T. Carpenter, Jr., MD, is a Professor of the University of Maryland School of Medicine and the Director of the Maryland Psychiatric Research Center. He obtained his medical degree from the Wake Forest University School of Medicine. After an internship at the North Carolina Baptist Hospital, he undertook postgraduate training at the University of Rochester Medical Center. He began his research career with the National Institute of Mental Health Intramural Program in 1966, using neuroendocrine strategies to study the psychobiology of affective disorders. He has also been a collaborating investigator with the World Health Organization’s International Pilot Study of Schizophrenia. Dr. Carpenter is the Editor-in-Chief for Schizophrenia Bulletin, has served on the editorial boards of the Archives of General Psychiatry, Biological Psychiatry, the Journal of Nervous and Mental Disease, Neuropsychopharmacology, Psychiatry Research, Schizophrenia Bulletin, Schizophrenia Research, Current Psychiatry Reports, and the CD-ROM version of the American College of Neuropsychopharmacology publication Neuropsychopharmacology: Fourth Generation of Progress, and has authored over 350 publications. Dr. Carpenter is Past-President of the American College of Neuropsychopharmacology, participated in the founding of the National Alliance for Research on Schizophrenia and Depression (NARSAD), and chairs the scientific program committee.

Dr. Carpenter’s major professional interest has been severe mental illness, especially schizophrenia, including phenomenology of the psychoses, and the etiology, pathophysiology, anatomy, and treatment of schizophrenia. He has made original and fundamental contributions in psychopathology, assessment methodology, testing of new treatments, and research ethics. His special professional assignments include service on the NIMH Intramural Research Program Board of Scientific Counselors and as a consultant and reviewer for NIMH and National Institutes of Health on many topics. He chaired the NIMH Research Scientist Career Development Committee and the NIMH National Schizophrenia Plan Committee on Treatment Research. Dr. Carpenter has served as Principle Investigator on five NIMH-funded research centers. He provided expert testimony in the cases of the United States Government v. John Hinckley and in 1989 was a member of the State Department delegation to inspect the political use of psychiatry in the Soviet Union. He chairs the work group responsible for psychotic disorders in preparation of DSM-V. He has been the recipient of national and international research awards including the Lieber Prize from NARSAD. Dr. Carpenter was elected to the Institute of Medicine of the National Academy of Sciences in 1998.
 


Francesc Colom, PsyD, MSc
Head of the Psychoeducation and Psychological Treatments Area
Barcelona Bipolar Disorders Program (IDIBAPS- Hospital Clinic University of Barcelona), Spain

Francesc Colom, PsyD, MSc, PhD received his Doctorate Cum Laude in Psychology and Master’s Degree in Social Psychiatry from the University of Barcelona (Spain), did Post-Graduate work in Psychobiology and Psychopharmacology at the University of Barcelona, and earned a Master’s Degree in Affective Neuroscience from the University of Maastricht (Netherlands).
Dr. Colom is the Head of the Psychoeducation and Psychological Treatments Area at the Barcelona Bipolar Disorders Program (IDIBAPS- Hospital Clinic University of Barcelona), which has conducted the largest psychoeducation controlled single-blind trial with bipolar patients. The Barcelona Psychoeducation Program, designed by Dr. Colom and his colleagues, is now the strongest evidence-based psychoeducational program for bipolar patients.

Dr. Colom has lectured all over the world and published almost 100 articles and book chapters on the subject of treatment compliance and psychoeducational issues in bipolar disorders. Dr. Colom has also authored 12 books on subjects related to affective disorders and their treatment with a view toward increasing general knowledge about bipolar disorders. In Spain, he is a frequent contributor to radio programs focusing on mental health issues. Dr. Colom’s research work centers on neuroplasticity and response to treatment, assessment, pharmacological issues, and clinical issues such as comorbidity, personality and the cognitive and neuropsychological factors related to bipolar disorders.

He has been a member of the Board of Councilors of the International Society for Bipolar Disorders. He is also a referee and member of the editorial board of several peer-reviewed journals and co-chairs the Spanish edition of the journal “Bipolar Disorders”. Dr.Colom is part of the Nomenclature Committee of the International Society for Bipolar Disorders, chairs the ISBD Website Education Committee for the same society, and is a member of the Scientific Advisory Panel of the ECNP. In addition to his other teaching responsibilities, Dr. Colom is privileged to hold a Honorary Senior Lecturer position at the Institute of Psychiatry of London. In June, 2007, Francesc Colom was awarded the prestigious “Mogens Schou Award” for the quality of his research. At present, he works for the IDIBAPS-Center of Biomedical Research in Mental Health (CIBERSAM.)


Allen S. Daniels, EdD
Executive Vice President and Director of Scientific Affairs, Depression and Bipolar Support Alliance
Professor of Clinical Psychiatry and Public Health Sciences
University of Cincinnati College of Medicine, Cincinnati, OH

On July 1, 2009 Allen Daniels will become the Executive Vice President and Director of Scientific Affairs for the Depression and Bipolar Support Alliance. Previously he has been a Professor of Clinical Psychiatry and Public Health Sciences at the University of Cincinnati, College of Medicine. Dr. Daniels is a graduate of The University of Chicago School of Social Services Administration, and The University of Cincinnati.
Dr. Daniels has participated on three Institute of Medicine study projects: “Crossing the Quality Chasm Priority Areas for Health Care Improvement” (2003), “Improving the Quality of Healthcare for Mental and Substance Use Conditions” (2006), and, Knowing What Works in Healthcare: A Roadmap for the Nation (2008). He has twice served as Chair of the Board of the American Managed Behavioral Healthcare Association (now Association for Behavioral Health and Wellness). He is active on a number of boards and professional organizations. Additionally, he has extensively published in the area of behavioral health policy including: managed care and group practice operations, quality improvement and clinical outcomes, behavioral healthcare workforce development, and behavioral health and primary care integration. He also lectures and consults both nationally and internationally on these subjects.


Wayne C. Drevets, MD
Senior Scientist and Chief, Section on Neuroimaging in Mood and Anxiety Disorders
Acting Chief, Laboratory on Molecular Pathophysiology
NIH/ NIMH/ DIRP Mood and Anxiety Disorders Research Program, Bethesda, MD

Wayne C. Drevets, M.D. joined the Intramural Research Program of the NIMH in 2001, after serving on the Psychiatry Department faculties of the University of Pittsburgh School of Medicine for four years and the Washington University School of Medicine for nine years. Dr. Drevets received his M.D. degree from the University of Kansas, and completed residency training in psychiatry at Washington University. Dr. Drevets’ research focuses on applying positron emission tomography (PET) and magnetic resonance imaging (MRI) to characterize the neurophysiological, receptor pharmacological, and neuroanatomical correlates of mood disorders. Dr. Drevets has been elected as a fellow in the American College of Neuropsychopharmacology, and serves on the Editorial Board for the journal, Biological Psychiatry. Dr. Drevets has authored or co-authored nearly 200 scientific articles and book chapters, and has been cited more than 9,000 times in the scientific literature.


Andrea Fagiolini, MD
Associate Professor of Psychiatry
University of Siena School of Medicine, Sienna, Italy
University of Pittsburgh School of Medicine, Pittsburgh, PA

Andrea Fagiolini received his medical training in Italy at the University of Pisa (Italy) School of Medicine and completed his psychiatric residency at the University of Modena (Italy) Medical School. Since 1998 he has been on the faculty at the University of Pittsburgh School of Medicine, in the Department of Psychiatry, where he has served as Medical Director of the Bipolar Disorder Center and of the Depression and Manic Depression Prevention Program. More recently, he has joined the faculty at the University of Siena School of Medicine, Siena Italy. He has published several books chapters and papers in peer reviewed international journals. His research interests and publications have primarily focused on Bipolar and Major Depressive disorders. The topics of his research include the pharmacological treatment of mood disorders, suicidality, functional impairment and quality of life in patients with bipolar disease, and the relationship between bipolar disorder and medical conditions such as obesity and other metabolic disturbances.


Jan Fawcett, MD
Professor of Psychiatry, University of New Mexico School of Medicine, Albuquerque, NM

Dr. Jan Fawcett, a graduate of Yale University School of Medicine, joined the Department of Psychiatry of the University of New Mexico School of Medicine, after thirty years of service as the Stanley Harris, Sr. Chairman of the Department of Psychiatry at Rush Medical College in Chicago. He has pursued a career of research in the treatment of affective disorders and the prevention of suicide since completing his fellowship at the National Institute of Mental Health Clinical Center in 1964. Dr Fawcett has been awarded the Dr. Jan Fawcett Humanitarian Award by the National Depressive and Manic Depressive Association (now the Depression and Bipolar Support Alliance), and lifetime research awards by the American Association of Suicidology and the American Foundation for Suicide Prevention. He was also presented the Menninger award by the American College of Physicians for his research in mental health in 2000. More recently in 2005, Dr Fawcett shared the Falcone Prize for affective disorders research from the National Alliance for Research in Schizophrenia and Depression (NARSAD). He is currently a principal investigator of the “Recurrent Depression Prevention with Medication and Cognitive Behavioral Therapy” project, a five year study funded by NIMH at Rush Medical Center in collaboration with investigators at Vanderbilt and the University of Pennsylvania. He is a co-author of the APA Practice Guidelines on the assessment and management of suicidal patients and is the chairperson of the DSM-V Mood Disorders Work Group from 2007-2012. Dr. Fawcett has always maintained an active clinical practice focusing on patients with treatment resistant major affective disorders and continues to do so in his work as a Professor at the University of New Mexico School of Medicine, Department of Psychiatry.


Debra Frankel, LCSW
Depression and Manic Depression Prevention Program
University of Pittsburgh School of Medicine and Western Psychiatric Institute and Clinic, Pittsburgh, PA

Debra Frankel is a trainer, supervisor and clinician at the University of Pittsburgh School of Medicine in the Depression and Manic Depression Prevention Program at Western Psychiatric Institute and Clinic. She was originally trained in Interpersonal Psychotherapy in 1985 and has treated numerous mood disorder patients using this modality. Ms. Frankel helped to modify interpersonal psychotherapy for bipolar disorder patients and has been training and supervising clinicians in IPSRT since 1995. She has participated in clinical trials involving both Interpersonal Therapy and Interpersonal Therapy and Social Rhythms Therapy. She serves as a training supervisor for research clinicians. She is a clinical supervisor at the University of Pittsburgh Graduate School in Psychology. She has a private practice specializing in mood and anxiety disorders. She received her undergraduate degree from Kenyon College in 1978 and her master’s degree from Columbia University School of Social Work in 1980.


Mark A. Frye, MD
Consultant and Professor of Psychiatry, Mayo College of Medicine
Director of the Mayo Mood Clinic and Research Program, Rochester, MN

Dr. Frye received his medical degree from the University of Minnesota and completed his psychiatric training at the UCLA Neuropsychiatric Institute. He completed a subsequent research fellowship in the Biological Psychiatry Branch at the National Institute of Mental Health (NIMH) in Bethesda, Maryland. While at NIMH, his area of research was focusing on the neurobiology of depression and bipolar disorder. Formerly the Director of the UCLA Bipolar Disorder Research Program (1998-2006), he is now the Director of the Mayo Mood Clinic and Research Program. His clinical interests are in bipolar disorder, depression, and alcoholism with a research focus on genomics, brain imaging, and neuroendocrinology of mood disorders and alcoholism.

He has received numerous honors and awards both as an educator and researcher, including 3 UCLA departmental medical student and resident teaching awards and the Gerald Klerman Young Investigator Award from the Depression and Bipolar Support Alliance.

He research funding has been from NIMH, The Stanley Medical Research Institute, The American Foundation for Suicide Prevention, and industry. He is an active author, publishing more than 120 papers in peer-reviewed publications such as the American Journal of Psychiatry, Journal of Affective Disorder, Journal of Clinical Psychiatry and Biological Psychiatry. Dr. Frye is on the editorial board of The Journal of Bipolar Disorders: Reviews & Commentaries and Acta Neuropsychiatrica. He has been recently elected to the Scientific Advisory Committee to the Depression and Bipolar Support Alliance and is the Vice President of Global Outreach for the International Society of Bipolar Disorder


John R. Geddes, MD, FRCPsych
Professor of Epidemiological Psychiatry, Department of Psychiatry, University of Oxford, Oxford, UK

John R. Geddes is Professor of Epidemiological Psychiatry at University of Oxford, UK. His current research focuses on conducting large scale randomized clinical trials and using research synthesis methods including systematic overviews and meta-analysis to inform clinical practice. Professor Geddes is Director of the Oxford Clinical Trials Unit for Mental Illness. Professor Geddes is Honorary Consultant Psychiatrist at the Oxfordshire and Buckinghamshire Mental Health NHS Foundation Trust where he provides clinical care for patients with mood disorders, specialising in bipolar disorder. Professor Geddes is a Fellow of the Royal College of Psychiatrists and, in 2008, was awarded an Honorary Fellowship of the American College of Psychiatrists. Professor Geddes has authored or co-authored, more than 150 scientific articles and book chapters and 4 books.


Elizabeth L. George, PhD
Licensed Clinical Psychologist
Research Associate, University of Colorado, Boulder, CO

Dr. George received her bachelor’s degree in English and Psychology at the University of North Carolina in Chapel Hill. She received her Ph.D. in Clinical Psychology from the University of Colorado in Boulder. She completed her residency at the Denver Veterans Administration Medical Center. Dr. George is a research associate at the University of Colorado-Boulder where she provides treatment, supervises, and continues to develop treatment outcome programs.

Dr. George has done extensive research in treatment development for bipolar disorder. She has spent 18 years involved in treatment outcome research for adult and adolescent bipolar disorder. She helped to develop Integrated Family and Individual Treatment (IFIT) for bipolar disorder. She co-wrote the manual for Family Focused Treatment (FFT) for adolescent bipolar disorder. Currently she is involved in an ongoing three site FFT treatment outcome study involving 150 families with an adolescent who has bipolar disorder. Dr. George has co-written a manual on a prevention treatment for youth (9-17) at risk for developing bipolar disorder and is involved in a two site outcome study for the at risk population. Dr. George and Dr. David Miklowitz have written a book for parents entitled The Bipolar Teen: What you can do to help your child and your family (2008) describing identification and treatment of adolescent bipolar disorder. Dr. George also provides trainings and lectures on many aspects of the bipolar condition and its treatment including comorbidity and managing bipolar in the academic environment.

In addition, Dr. George has an active private practice that primarily focuses on treatment of bipolar II and the bipolar spectrum disorders. She is also the community advisor for the Boulder chapter of the Depression and Bipolar Support Alliance (DBSA). She continues to be interested in finding new ways to understand and treat this medically complicated illness.


S. Nassir Ghaemi, MD, MPH
Director, Mood Disorders and Psychopharmacology Programs, Tufts Medical Center, Boston, MA

S. Nassir Ghaemi MD, MPH is a psychiatric researcher with expertise in bipolar disorder, and training in philosophy and public health. He is the author of A Clinician's Guide to Statistics and Epidemiology in Mental Health: Measuring Truth and Uncertainty, published in 2009 by Cambridge University Press. Previous books he has authored include The Concepts of Psychiatry: A Pluralistic Approach to the Mind and Mental Illness (Baltimore, Maryland: Johns Hopkins University Press, 2003, 2007), as well as the 2nd edition of Mood Disorders: A Practical Guide (Baltimore, Maryland: Lippincott, Williams, and Wilkins; 2003, 2007). He has also published over 100 scientific articles or book chapters, and serves on the editorial board of numerous journals. He also serves on the executive committee of the Association for the Advancement of Philosophy and Psychiatry; is a Distinguished Fellow of the American Psychiatric Association; and has served as chairman of the Diagnostic Guidelines Task Force of the International Society for Bipolar Disorders (2005-2008). Dr. Ghaemi obtained his medical degree at the Medical College of Virginia (MCV) in Richmond, completed a medical internship at Massachusetts General Hospital (MGH) in Boston, psychiatry residency at McLean Hospital in Belmont, Massachusetts, and a research psychopharmacology fellowship in mood disorders at MGH, followed by faculty positions at George Washington University, Harvard Medical School, and Emory University. He also received a Master of Arts degree in philosophy from Tufts University in 2001 and a Master of Public Health degree in the Clinical Effectiveness Program from the Harvard School of Public Health in 2004.


Jodi M. Gonzalez, PhD
Assistant Professor, University of Texas Health Science Center in San Antonio, TX

Jodi M. Gonzalez obtained her PhD in Counseling Psychology from the University of North Texas in 1999. Her internship and postdoctoral fellowship were completed at the University of Texas Health Science Center at San Antonio, with an emphasis on clinical research. Dr. Gonzalez joined the faculty as an assistant professor at the University of Texas Health Science Center in San Antonio in the Mood and Anxiety Disorders Division in 2000. She is a recipient of a 2007 NARSAD Young Investigator Award to develop and manualize psychodynamic psychotherapy techniques in complicated bipolar disorder. She is currently involved in several community-based research projects and serves as the chair of the Diversity Committee of the multi-site Bipolar Trials Network. Additional areas of research interest and publications are: psychosocial treatment in bipolar disorder, attitudes toward mental health treatment, adherence to treatments, and the impact of ethnicity/race in each of these areas. She lectures and supervises medical students, psychiatry and psychology residents. In particular, she supervises and teaches in psychotherapy models and treatments. Dr. Gonzalez is a licensed psychologist and provides individual and family psychotherapy for adolescents and adults.


Guy Goodwin, DPhil, FMedSci
W A Handley Professor of Psychiatry, University of Oxford, Oxford, England

Guy Goodwin trained in medicine and completed a DPhil in physiology at Oxford. After training in psychiatry he was for 10 years Clinical Scientist and Consultant Psychiatrist in the MRC Brain Metabolism Unit in Edinburgh. Since 1996 he has been Professor of Psychiatry and head of the University department in Oxford. Dr. Goodwin’s research interests are in the treatment of severe psychiatric illness and the application of neuroscience in understanding the neurobiology of mood disorder. Currently, he is involved in projects on the neurobiology of vulnerability to mood disorder, the psychopharmacology of emotional processing. He has also helped develop the basis for larger scale pragmatic clinical trials in bipolar affective disorder (BALANCE and CEQUEL). Dr. Goodwin has served as a member of the Wellcome Trust Neurosciences Panel, the Council of the British Association for Psychopharmacology, the Clinical fellowships panel and Advisory Board of the MRC and the French ANR. He was president of the British Association for Psychopharmacology 2002-2004 and is a member of ACNP. He has published over 300 refereed papers and book chapters. He has acted as a reviewer for numerous journals including the American Journal of Psychiatry, The Archives of General Psychiatry, and Biological Psychiatry. Dr. Goodwin remains directly involved in patient care, almost exclusively focused on bipolar disorders.


Allison G. Harvey, PhD
Associate Professor of Psychology, Department of Psychology
University of California at Berkeley, Berkeley, CA

Allison G. Harvey, PhD., completed her clinical and research training in Sydney, Australia, a post doctoral fellowship and her first faculty position at the University of Oxford before moving to the Psychology Department at UC Berkeley in 2004. Dr. Harvey’s research focuses on understanding the role of sleep disturbance across psychiatric disorders, particularly bipolar disorder. Dr. Harvey has authored over 100 scientific articles and book chapters and authored two books. She has been the recipient of numerous awards, including The Queen’s Trust Award and the Chaim Danielle Award for Traumatic Stress Studies. Dr. Harvey has received research funding from the Royal Society, Wellcome Trust, NARSAD and the National Institutes of Mental Health.


Aude Henin, PhD
Director, Cognitive-Behavior Therapy Program
Clinical and Research Program in Pediatric Psychopharmacology
Massachusetts General Hospital
Assistant Professor of Psychology, Harvard Medical School, Boston, MA

Dr. Henin received her undergraduate degree from McGill University and her doctoral degree in clinical psychology from Temple University. She completed a pre-doctoral internship and post-doctoral fellowship at Massachusetts General Hospital, Harvard Medical School, where she subsequently joined the faculty in 2001. Dr. Henin’s research focuses on neurocognitive factors associated with bipolar disorder in children, as well as the efficacy of cognitive behavioral treatments for youth with severe psychiatric disorders, including bipolar disorder. Her research is funded by the National Institute of Mental Health, NARSAD, Harvard University, and the MGH, and she has received honors from organizations such as the American Psychological Association, and the Anxiety Disorders Association of America. She has authored or co-authored over 50 articles, chapters, and books.


Chantal Henry, MD, PhD
Professor of Psychiatry
University of Paris XII and Chenevier Hospital
Créteil, France

Chantal Henry, MD, PhD, joined the faculty of the University of Paris XII in September, 2008 as Professor of Psychiatry after 14 years at the Bordeaux hospital. Dr. Henry’s research focuses on the assessment and treatment of mood disorders, with a particular interest in emotional reactivity to define mood episodes and intercrisis period. She works also on the identification of relevant phenotypes for genetic studies on bipolar disorders. Since 2008, Dr. Henry has been in charge of the organization of French networks of expert centres on bipolar disorders, schizophrenia and Asperger. She coordinates also a European project: ENBREC (European Network of Bipolar Research Expert Centres). Dr. Henry has authored or co-authored more than 80 scientific articles, book chapters and books.


Thomas R. Insel, MD
Director, National Institute of Mental Health
Bethesda, MD

Thomas R. Insel, M.D., is Director of the National Institute of Mental Health (NIMH), the component of the National Institutes of Health charged with generating the knowledge needed to understand, treat, and prevent mental disorders.

Immediately prior to his appointment as Director, which marks his return to NIMH after an 8-year hiatus, Dr. Insel was Professor of Psychiatry at Emory University. There, he was founding director of the Center for Behavioral Neuroscience, one of the largest science and technology centers funded by the National Science Foundation and, concurrently, director of an NIH-funded Center for Autism Research. From 1994 to 1999, he was Director of the Yerkes Regional Primate Research Center in Atlanta. While at Emory, Dr. Insel continued the line of research he had initiated at NIMH studying the neurobiology of complex social behaviors in animals. Early in his NIMH research career, which extended from 1979 to 1994, Dr. Insel conducted clinical research on obsessive-compulsive disorder, conducting some of the first treatment trials for OCD using the selective serotonin reuptake inhibitors (SSRI) class of medications. He has published over 200 scientific articles and four books, including the Neurobiology of Parental Care (with Michael Numan) in 2003.

Dr. Insel has served on numerous academic, scientific, and professional committees, including 10 editorial boards. He is a member of the Institute of Medicine, a fellow of the American College of Neuropsychopharmacology, and is a recipient of several awards [A. E. Bennett Award from the Society for Biological Psychiatry, Curt Richter Prize from the International Society of Psychoneuroendocrinology, Outstanding Service Award from the U.S. Public Health Service, and a Distinguished Investigator Award from the National Alliance for Research on Schizophrenia and Depression (NARSAD)]. Dr. Insel graduated from the combined B.A.-M.D. program at Boston University in 1974. He did his internship at Berkshire Medical Center, Pittsfield, Massachusetts, and his residency at the Langley Porter Neuropsychiatric Institute at the University of California, San Francisco.


Kay Redfield Jamison, PhD
Professor of Psychiatry, Johns Hopkins University School of Medicine
Co-director, Johns Hopkins Mood Disorders Center, Baltimore, MD

Kay Redfield Jamison is Professor of Psychiatry at the Johns Hopkins University School of Medicine and co-director of the Johns Hopkins Mood Disorders Center. She is also Honorary Professor of English at the University of St. Andrews in Scotland. She is co-author of the standard medical text on manic-depressive illness, which was chosen in 1990 as the most outstanding book in biomedical sciences by the American Association of Publishers, and author of Touched with Fire, An Unquiet Mind, Night Falls Fast, and Exuberance. Dr. Jamison has written more than 100 scientific articles about mood disorders, suicide, creativity, and lithium. Her memoir, An Unquiet Mind, which chronicles her own experience with manic-depressive illness, was cited by several major publications as one of the best books of 1995. It was on The New York Times bestseller list for five months and translated into twenty languages. Night Falls Fast: Understanding Suicide was a national bestseller and selected by The New York Times as a Notable Book of 1999. Her most recent book, Exuberance: The Passion for Life, was selected by The Washington Post, The Seattle Times, and The San Francisco Chronicle as one of the best books of 2004 and by Discover magazine as one of the best science books of the year. Dr. Jamison is the recipient of numerous national and international scientific awards, including a MacArthur Award.


Terence Ketter, MD
Chief, Stanford University Bipolar Disorders Clinic and Professor of Psychiatry and Behavioral Sciences
Stanford University, Palo Alto, CA

Terence Ketter received his medical degree from the University of Toronto, completed internship and residency training at the University of California San Francisco, and fellowship training in psychopharmacology and brain imaging and at the National Institute of Mental Health in Bethesda. He is Chief of the Stanford University Bipolar Disorders Clinic and Professor of Psychiatry and Behavioral Sciences. Dr. Ketter’s research interests include the use of brain imaging methods such as magnetic resonance imaging (MRI), magnetic resonance spectroscopy (MRS), and positron emission tomography (PET) to better understand the neurobiology of mood disorders and to explore the possibility of using these techniques to more effectively target treatments for patients with bipolar disorders. Dr. Ketter has also done research in the use of novel medications and combinations of medications in the treatment of bipolar disorders, with an emphasis on the use of anticonvulsants. Recently his research group's work has revealed new insights into the links between creativity, temperament, and mood disorders. His research in these areas has been published extensively. He has published over 260 scientific articles and book chapters and is the editor of the book “Advances in the Treatment of Bipolar Disorder” and the forthcoming volume “Clinical Manual of Bipolar Disorder”.


Amy M. Kilbourne, PhD, MPH
Associate Professor of Psychiatry, University of Michigan
Associate Director, VA National Serious Mental Illness Treatment
Research and Evaluation Center, Ann Arbor, MI

Dr. Amy Kilbourne is a health services researcher focused on improving the quality and outcomes of medical care for persons with mental disorders. She is Associate Professor of Psychiatry at the University of Michigan and Associate Director of the VA Ann Arbor National Serious Mental Illness Treatment Research and Evaluation Center (SMITREC). Dr. Kilbourne’s current research is focused on dissemination and implementation strategies to improve quality of care and outcomes for persons with mental disorders. She has an RO1 focused on testing implementation strategies to improve quality and outcomes for persons with bipolar disorder in community-based practices (MH79994) and two intervention trials from NIMH (MH74509) and VA (CSRD) focused on reducing cardiometabolic risk in patients with mental disorders. She has over 80 publications focused on mood disorders (including bipolar disorder), quality of care for persons with mental disorders, health disparities, implementation science, and medical outcomes. Dr. Kilbourne currently serves on several national committees dedicated to improving outcomes for persons with mental disorders in the VA and elsewhere and regularly consults with decision makers at community-based practices on implementing interventions to integrate care and improve quality for persons with mental disorders. Dr. Kilbourne graduated from the University of California at Berkeley with a double major in molecular biology and rhetoric. She has both a Masters Degree of Public Health in Epidemiology and a Ph.D. in Health Services from the University of California, Los Angeles.


Marion Leboyer, MD, PhD
Professor of Psychiatry, University of Paris XII
Department of Psychiatry and Psychiatry Genetic Lab, INSERM, Paris, FRANCE

Marion Leboyer, M.D., Ph.D. joined the faculty of the University of Paris in 1998 as Professor of Psychiatry. She is head of the university affiliated department of Psychiatry (Hospital Chenevier-Mondor, AP-HP) and runs a Psychiatry Genetics laboratory (INSERM). Dr. Leboyer’s research efforts have contributed to a better identification of relevant phenotype for genetic studies, particularly in the field of bipolar disorder, schizophrenia, suicide, autism, OCD and pharmaco-genetic studies. Being principal investigator of national and international studies, she has been able to produce prominent findings such as identification in autism of the first mutations in neuroligins (NLGN-3 and NLGN-4). She is director of .a foundation (FondaMental) recently created by the French Ministry of Research aiming at creating a network of expert centers and promoting research in Psychiatry. Dr. Leboyer has authored or co-authored more than 200 scientific articles and book chapters, as well as 5 books.


Ellen Leibenluft, MD
Senior Investigator and Chief of the Section on Bipolar Spectrum Disorders
Emotion and Development Branch, Mood and Anxiety Program
National Institute of Mental Health, Bethesda, MD

Ellen Leibenluft, M.D. is Senior Investigator and Chief of the Section on Bipolar Spectrum Disorders in the Emotion and Development Branch, Mood and Anxiety Program, National Institute of Mental Health. Her research focuses on the brain mechanisms mediating bipolar disorder in youth, and on the phenomenology and pathophysiology of severe irritability in children. Dr. Leibenluft received her B.A. from Yale University summa cum laude and her M.D. from Stanford University. After completing residency training at Georgetown University Hospital, she served on the faculty there as director of the psychiatric inpatient unit and day hospital. She came to the NIMH in 1989, and since then has been conducting research on bipolar disorder. She has more than 100 professional publications and is a Deputy Editor of the Journal of the American Academy of Child and Adolescent Psychiatry and a member of the editorial boards of the American Journal of Psychiatry, Biological Psychiatry, Bipolar Disorders, Depression and Anxiety, and the Journal of Child and Adolescent Psychopharmacology. Dr. Leibenluft is a member of the American College of Neuropsychopharmacology and the American Psychiatric Association Work Groups on Childhood Disorders and Mood Disorders for DSM-V. Her awards include the Distinguished Psychiatrist Award of the American Psychiatric Association, Special Service Awards from the NIH, and the NIMH and NIH Outstanding Mentor Awards.


Husseini K. Manji, MD, FRCPC
Global Head, Neuroscience, Johnson & Johnson Pharmaceutical Research and Development, Titusville, NJ
Visiting Professor, Department of Psychiatry, Duke University, Durham, NC

Husseini K. Manji, MD is Global Head, Neuroscience, Johnson and Johnson Pharmaceutical Research and Development. He was previously Chief, Laboratory of Molecular Pathophysiology & Experimental Therapeutics, NIMH, and director of the NIH Mood and Anxiety Disorders Program, the largest program of its kind in the world. He is also a visiting professor in the Department of Psychiatry at Duke University. Dr. Manji received his B.S. (Biochemistry) and M.D. from the University of British Columbia. Following residency training, he completed fellowship training at the NIMH and obtained extensive additional training in cellular and molecular biology at the NIDDK. The major focus of his research has been the investigation of disease- and treatment-induced changes in gene and protein networks that regulate synaptic and neural plasticity in neuropsychiatric disorders. His work has helped to conceptualize these illnesses as genetically-influenced disorders of synaptic and neural plasticity, and has led to the investigation of novel therapeutics for refractory patients. He has also been actively involved in the development of biomarkers to help refine these multifactoral diseases into mechanism-based subcategories to develop targeted therapeutics. Dr. Manji is a previous recipient of numerous research awards, including the NIMH Director's Career Award for Significant Scientific Achievement, the A. E. Bennett Award for Neuropsychiatric Research, the Ziskind-Somerfeld Award for Neuropsychiatric Research, the NARSAD Mood Disorders Prize, the Mogens Schou Distinguished Research Award, the American College of Neuropsychopharmacology (ACNP)’s Joel Elkes award for distinguished research, the Canadian Association of Professors in Psychiatry Award, the Henry and Page Laughlin Distinguished Teacher Award, the Brown University School of Medicine Distinguished Researcher Award, the DBSA Klerman Senior Distinguished Researcher Award, and the NIMH award for excellence in clinical care and research. In addition to his neuroscience research, and biomarker and innovative therapeutics development endeavors, Dr. Manji has also been actively involved in medical and neuroscience education undertakings, and has served as a member of the National Board of Medical Examiners (NMBE) Behavioral Science Test Committee, the Howard Hughes Medical Institute Research Scholars Program Selection and Advisory Committee, and numerous national curriculum committees. He has developed and co-directed the NIH Foundation for the Advanced Education in the Sciences Graduate Course in the Neurobiology of Mental Illness, and has received both the NIMH Mentor of the Year and NIMH Supervisor of the Year awards. He has published extensively on the molecular and cellular neurobiology of severe neuropsychiatric disorders and the development of novel therapeutics. He has been editor of Neuropsychopharmacology Reviews: the next generation of progress, deputy editor of Biological Psychiatry, associate editor of the journal Bipolar Disorders, and sits on the editorial board of numerous journals. Dr. Manji has been inducted into the National Academy of Sciences’ Institute of Medicine (IOM), is a Councilor of the ACNP, chaired the ACNP’s Task Force on New Medication Development, and is president of the Society of Biological Psychiatry.


Colleen A. McClung, PhD
Assistant Professor of Psychiatry, University of Texas, Southwestern Medical Center, Dallas, TX

Dr. McClung received her bachelor’s degree in biology from the University of North Carolina at Chapel Hill in 1994 and then her Ph.D. from the University of Virginia in 2001. As a graduate student she pioneered the use of the fruit fly, Drosophila, as a model system to study the genes involved in drug addiction. She went on to do a postdoctoral fellowship with Dr. Eric Nestler at UT Southwestern where she continued her studies of the molecular mechanisms of addiction. She joined the faculty in the Department of Psychiatry in 2005 and has since expanded her interests into other psychiatric disorders, particularly bipolar disorder. She has received numerous awards and grants including two NARSAD young investigator awards, The McKnight foundation Neuroscience of Brain Disorders Award, the UTSW President’s Research Council Distinguished Young Investigator Award, the Sarah Tierney Arnold Memorial Award, as well as several awards from the NIH. She has authored several articles, book chapters and reviews and her research into the role of circadian rhythms in bipolar disorder has been featured prominently in both the scientific and popular press.


Jim McNulty
Vice President of Peer Support, Depression and Bipolar Support Alliance
Project Director, Peers Helping Peers Center, Chicago, IL

Jim McNulty is the Vice President of Peer Support for the Depression and Bipolar Support Alliance. He is the Project Director for the Peers Helping Peers Center, a National Consumer Technical Assistance Center. The Center is funded by a grant from the Center for Mental Health Services, Substance Abuse Mental Health Services Administration, U.S. Department of Health and Human Services.

McNulty has served as the Director of the Office of Consumer Affairs for the Division of Behavioral Health state of RI, and Magellan Health Services’ Director of Consumer and Recovery Services. He is Past President of the National Alliance on Mental Illness (NAMI National). He served a 4 year term on the National Advisory Mental Health Council for the NIMH, and currently serves on the SAMHSA/CMHS National Advisory Council, and is chair of the Subcommitee on Consumer/Survivor issues. He is serving as a member of the board of directors of the American Association of Human Research Protection Programs, an accrediting body for research organizations.
He is a member of the American Psychiatric Association’s Task Force for the 5th edition of the Diagnostic and Statistical Manual. He continues to serve as the President of the MDDA of RI (an affiliate of DBSA), a support and advocacy group for people who share the lived experience mental disorders. He also serves on the board of directors of the Mental Health Consumers of RI.


David J. Miklowitz, PhD
Professor of Psychology and Psychiatry, University of Colorado, Boulder CO, USA
Senior Clinical Researcher, Department of Psychiatry, Warneford Hospital, Oxford University, Oxford, UK

Dr. Miklowitz is Professor of Psychology and Psychiatry at the University of Colorado (Boulder and Health Sciences Center Campuses), and a Senior Clinical Research Fellow in the Department of Psychiatry at Oxford University. He completed his undergraduate work at Brandeis University and his doctoral (1979-1985) and postdoctoral (1985-1988) work at UCLA. His research focuses on family environmental factors and family psychoeducational treatments for adult-onset and childhood-onset bipolar disorder.
Dr. Miklowitz has received the Joseph Gengerelli Dissertation Award from UCLA (1986), Young Investigator Awards from the International Congress on Schizophrenia Research (1987) and the National Alliance for Research on Schizophrenia and Depression (NARSAD; 1987), a Faculty Research Award (1998) and a Faculty Teaching Award (2008) from the University of Colorado, and a Distinguished Investigator Award from NARSAD (2001). He won the 2005 Mogens Schou Award for Research. He has received funding for his research from the National Institute of Mental Health, the John D. and Catherine T. MacArthur Foundation, the Robert Sutherland Foundation, and the Danny Alberts Foundation. He currently holds two major NIMH grants and two private foundation grants.

Dr. Miklowitz has published over 200 research articles and book chapters on bipolar disorder and schizophrenia, and four books. His articles have appeared in the Archives of General Psychiatry, the American Journal of Psychiatry, the British Journal of Psychiatry, the Journal of Nervous and Mental Disease, Biological Psychiatry, the Journal of Consulting and Clinical Psychology, and the Journal of Abnormal Psychology. His book with Michael Goldstein, Bipolar Disorder: A Family-Focused Treatment Approach (Guilford), won the 1998 Outstanding Research Publication Award from the American Association for Marital and Family Therapy. His book “The Bipolar Disorder Survival Guide” is the second best-selling book on bipolar disorder, having sold over 180,000 copies. His latest book, also with Guilford, is titled The Bipolar Teen: What You Can Do to Help Your Teen and Family.


Philip Mitchell MB BS (Hons I), MD, FRANZCP, FRCPsych
Scientia Professor and Head of the School of Psychiatry
University of New South Wales, Sidney, Australia

Philip Mitchell MB BS (Hons I), MD, FRANZCP, FRCPsych is Scientia Professor and Head of the School of Psychiatry at the University of New South Wales; Convenor of Brain Sciences UNSW; Chair of the NSW Mental Health Priority Taskforce; Consultant Psychiatrist, Prince of Wales Hospital and Black Dog Institute, Sydney; Guest Professor, Shanghai Jiaotong University; and Board Member of the Anika Foundation.

His research and clinical interests are in bipolar disorder and depression, with a particular focus on: molecular genetics of bipolar disorder; predictors of the development of bipolar disorder in at-risk individuals; pharmacological and psychological treatments for bipolar disorder and depression; clinical phenomenology of bipolar disorder and depression; and stimulatory therapies for depression (such as transcranial magnetic stimulation and direct current stimulation).

Professor Mitchell has published (in conjunction with colleagues) over 300 peer-reviewed papers or book chapters on these topics and is a member of an NHMRC-funded Program Grant on depression and bipolar disorder. He is an assistant editor of the ‘Australian and New Zealand Journal of Psychiatry’ and also serves on the editorial boards of ‘Psychiatric Genetics’, ‘CNS Drugs’, ‘Current Therapeutic Research’ and ‘Medicine Today’.

In 2002 Prof. Mitchell was awarded the Senior Research Award of the Royal Australian and New Zealand College of Psychiatrists. In 2004, he received the Founders Medal of the Australasian Society for Psychiatry Research. In 2006, he received a Medical Media award from Research Australia for his media commentary on a wide range of mental health issues. In 2008, he received a Rotary International Vocational Excellence Award which recognizes outstanding contributions made by individuals or teams for significant advancement in their field in Australia. In 2008, he was invited to give the endowed Samuel Novey Lecture in Psychological Medicine at Johns Hopkins University, Department of Psychiatry and Behavioral Sciences. Professor Mitchell also serves on the NSW Health Care Advisory Council.


Bruno Müller-Oerlinghausen, DrMed
Professor of Clinical Psychopharmacology and Chief of the Laboratory of Clinical Psychopharmacology
Freie Universität Berlin, Germany

Bruno Müller-Oerlinghausen, DrMed was born 1936 in Berlin, obtained his training in medicine at the universities of Göttingen, Munich, Francfort/M., Freiburg, and Berlin (West). 1964 to 1969 he underwent a postgraduate training in pharmacology and toxicology at the Department of Pharmacology, University of Goettingen, and qualified as a lecturer in pharmacology and toxicology with a thesis on “Hormonal influence on mechanisms of hepatic detoxification”.

1969 to 1971 he was assigned to the Department of Medical Sciences (Ministry of Public Health) in Bangkok (Thailand) by the government of the Federal Republic of Germany as an expert in pharmacology. He built up a pharmacological research lab and trained the Thai staff in methods to investigate the pharmacology of old-style herbal medicine.

In 1971 Dr. Müller-Oerlinghausen entered the Department of Psychiatry, Freie Universität Berlin, for additional training in clinical psychiatry, and in 1974 he was appointed as Chief Scientist of the Lithium Clinic Berlin, and at the same time promoted to Professor of Clinical Psychopharmacology and Chief of the Laboratory of Clinical Psychopharmacology. For 27 years he was editor-in-chief of Pharmacopsychiatry, and he is associate editor of many other journals, such as Bipolar Disorders, Journal of Psychiatry and Neuroscience, or Drug Research; etc. 1983 to 1987 he was elected as president of AGNP (Association for Neuropharmacology of the German speaking countries), 1982 to 1988 he served as Councillor of the Executive Board of CINP. In 2001 he retired from his academic duties at the Freie Universität Berlin. 1994-2006 he has been re-elected three times as the acting chairman of the Drug Commission of the German Medical Association and retired from this position at the end of 2007.

His scientific interests were mainly related to the clinical pharmacology of antidepressants, neuroleptics and particularly lithium salts in humans. Recent work focussed on long-term effects of lithium salts with special regard to its serotonergic action including anti-aggressive and antisuicidal effects; serotonergic mechanisms in patients with affective disorders; genetic studies in depression and in clozapine-induced agranulocytosis. He has been a principal investigator in large national and international studies on the suicide preventive effects of lithium supported by the Federal Ministry of Research and the German Research Council (DFG).

In recent years he conducted a clinical trial investigating the effects of slow-stroke-massage in depressed patients and healthy volunteers.

Dr. Müller-Oerlinghausen has been a member of the Steering Committees of national research institutions, e.g. the Association of Clinical Pharmacology Berlin/Brandenburg, and the Research Network on Depression and Suicide, both financed by the Federal Ministry of Research and Technology. He is a member of the Association for Neuropharmacology and Pharmacopsychiatry of the German Speaking Countries (AGNP), the European College of Neuropsychopharmacology (ECNP), Collegium Internationale Neuro-Psychopharmacologicum (C.I.N.P.), the International Society for Bipolar Disorders (ISBD), the German Association of Pharmacology and Toxicology, the German Association of Clinical Pharmacology, the Drug Commission of the German Medical Association, the German Association of Bipolar Disorders, and others.
He has written more than 600 publications as first author and co-author, and fourteen monographies as editor or co-editor. Honors include the Research Award 2004 by the American Foundation for Suicide Prevention New York; 2006 Ernst-von-Bergmann-Awarding by the President of German Medical Association; and 2007 Paracelsus-Medal conferred by the Deutsche Ärztetag (Münster May 2007)


Willem A. Nolen, MD, PhD
Professor of Psychiatry
Head of Department for Affective Disorders, Department of Psychiatry
University Medical Center Groningen, Groningen, The Netherlands

Willem A. Nolen is scientific coordinator for the clinical studies in affective disorders at the University of Groningen and principal investigator for the Groningen site of the Netherlands Study on Depression and Anxiety (NESDA), a Dutch multi-center 8 year follow-up study in respondents (n=2,981) with depressive and/or anxiety disorders.

His major research interest is mood disorders, both bipolar disorder and major depression, in which he is conducting research on epidemiology, etiology, long-term course and treatment. A main part of his research has focused on the different pharmacological treatment options in bipolar and unipolar mood disorders and their place in guidelines and algorithms. Dr, Nolen has published over 350 papers, many of them in international journals or as chapters in international books. He has been a member of the editorial board of the Dutch Journal of Medicine (NTvG) and of the Dutch Journal of Psychiatry (TvP), is currently a member of the editorial board of Bipolar Disorders, and serves as an editorial consultant for several international journals.  In 2007 he received the annual award for scientific research of the Dutch Psychiatric Association (NVvP).


Maria A. Oquendo, MD
Professor of Clinical Psychiatry, Columbia University, and Vice-Chair for Education
Department of Psychiatry at Columbia University and the New York State Psychiatric Institute, New York, NY

Maria A. Oquendo, M.D. is Professor of Clinical Psychiatry at Columbia University and Vice-Chair for Education in the Department of Psychiatry at Columbia University and the New York State Psychiatric Institute (NYSPI). Her areas of expertise include suicidal behavior and the diagnosis, pharmacologic treatment, and neurobiology of Bipolar Disorder and Major Depression, as well as Cross Cultural Psychiatry.

Dr. Oquendo graduated summa cum laude and Phi Beta Kappa from Tufts University in 1980. She received her M.D. from the College of Physicians and Surgeons at Columbia University in 1984. She completed her residency in Psychiatry at the Payne Whitney Psychiatric Clinic in the New York Hospital-Cornell Medical Center. She is the principal investigator on a NIMH funded prospective study of suicidal behavior in patients with affective disorders. She is the Co-Principal Investigator on a NIAAA funded Developing Center for Interventions to Prevent Suicide. She is also a co-investigator on four other NIMH-funded research studies examining the neurobiology of suicidal behavior. She is the recipient of a grant from the American Foundation for Suicide Prevention for the study of serotonin transporter binding using PET in bipolar suicide attempters, non attempters and healthy volunteers and of an NIMH grant to study high-risk suicide attempters with Bipolar Disorder.

Dr. Oquendo teaches at Columbia University. She is a member of the American Psychiatric Association, the American College of Neuropsychopharmacology, Group for the Advancement of Psychiatry, Association of Women Psychiatrists, APA Committee on Research Training, and the American Board of Psychiatry and Neurology, on which she also functions as an examiner. She is the president-elect of the American Society of Hispanic Psychiatry and chairwoman of the APA SAMHSA Fellowship and Selection Corresponding Committee. She is an associate editor of the American Journal of Psychiatry and serves on the Scientific Advisory Council of the American Foundation for Suicide Prevention. She is a member of the NIMH scientific review committee, Interventions and Treatment of Mood and Anxiety Disorders (ITMA) responsible for providing peer review of applications for federally funded grants. She has authored or co-authored over 200 peer-reviewed articles, chapters, and editorials. She is the recipient of several awards including Exemplary Psychiatrist Award from the National Alliance for the Mentally Ill (1993); Award from the National Alliance for the Mentally Ill for Commitment to Multicultural and Underserved Communities (2002); Travel Award from American Foundation for Suicide Prevention (2003); the Marian Butterfield Early Career Psychiatrist Award from the Association of Women Psychiatrists (2004); the Gerald Klerman Award from the Depression and Bipolar Support Alliance (2005); Distinguished Psychiatrist Lecture in the Annual Meeting of the American Psychiatric Association (2008) and the Aaron Bailey Lecturer from the University of Colorado (2009).


Michael W. Otto, PhD
Professor of Psychology, Director, Center for Anxiety and Related Disorders Boston University, Boston, MA

Michael W. Otto, Ph.D., is Professor of Psychology, and Director, Center for Anxiety and Related Disorders at Boston University. Dr. Otto specializes in the cognitive-behavioral treatment (CBT) of anxiety, mood, sleep, and substance use disorders. An enduring theme across these disorders is the role of exposure-based emotional tolerance/acceptance strategies in improving mental health. Dr. Otto has a history of federal funding from NIMH and NIDA, and his research focuses on difficult-to-treat populations, including the application of cognitive-behavioral strategies to patients who have failed to respond to previous interventions, as well as developing novel strategies for bipolar disorder and substance use disorders. Current research at the Center for Anxiety and Related Disorders includes investigations of potential moderators of CBT efficacy, including several translational-research agendas ranging from studies of de novo fear conditioning to the application of putative memory enhancers (e.g., d-cycloserine) to facilitate exposure-based treatments. Dr. Otto has published over 250 articles, chapters, and books spanning his research interests, and was recently identified as a “top producer” in the clinical empirical literature. For clinical training, he has numerous treatment manuals published in the Treatments That Work series for Oxford University Press. Dr. Otto is past President of the Association for Behavioral and Cognitive Therapies (formerly AABT), a fellow of the American Psychological Association, and a member of the Scientific Advisory Board for the Anxiety Disorders Association of America. Dr. Otto is a regular provider of continuing education and continuing medical education workshops across the United States.


Sagar V. Parikh, MD, FRCPC
Deputy Psychiatrist-in-Chief, University Health Network
Director of Continuing Mental Health Education and Professor of Psychiatry
University of Toronto, Toronto, Canada

Dr. Parikh is Deputy Psychiatrist-in-Chief at the University Health Network and director of Continuing Mental Health Education at the University of Toronto, where he also is Professor of Psychiatry. Dr. Parikh is the author / editor of two books and over 100 peer reviewed articles and book chapters. Research interests include clinical treatments in mood disorders, health services research, genetics, epidemiology, and educational research. He was awarded the Dave Davis CEPD Research Award from the University of Toronto in 2008. He also is a co-author of CANMAT treatment guidelines for Depression and for Bipolar Disorder, Secretary of the International Society for Affective Disorders, and Head, Section of Affective Disorders, World Psychiatric Association. As medical director of Mensante, he helped create a novel internet system for recognition and management of mental disorders. He was honored by the Canadian Psychiatric Association by delivering the Distinguished Member Lecture at the 2007 CPA Annual Meeting. His teaching has won him three local, two national, and one international awards, most recently the Association of Chairs of Psychiatry Award for Excellence in Education in 2005.


Mary L. Phillips, MD
Professor of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA

Professor Mary Phillips trained at Cambridge University and the Maudsley Hospital and Institute of Psychiatry, UK. She became Professor of Psychiatry, Institute of Psychiatry, UK in 2003, and, in 2006, Professor in Psychiatry in the Department of Psychiatry, University of Pittsburgh. In 2008, she became Professor in Clinical Affective Neuroscience in the Department of Psychological Medicine, Cardiff University, UK. She now heads research teams in Pittsburgh and Cardiff, focusing on identification of neural system abnormalities underlying abnormal emotion processing in mood disorders. She is mentor to nearly 30 junior investigators and has authored or co-authored over 140 publications.


Darrel A. Regier, MD, MPH
Director, APA Division of Research; Executive Director, APIRE; and Vice-Chair, DSM-V Task Force
Arlington, VA

Dr. Regier has served for the past nine years as Executive Director of the American Psychiatric Institute for Research and Education (APIRE), as well as Director, Division of Research at the American Psychiatric Association (APA). A principle responsibility has been to coordinate the maintenance and revision plans for the APA’s Diagnostic and Statistical Manual. In 2006, he was named Vice-Chair of the DSM-V Revision Task Force to work jointly with the Task Force Chair, Dr. David Kupfer. Prior to taking this position, Dr. Regier completed 25 years at the National Institute of Mental Health (NIMH), during which time he directed three research divisions in the areas of epidemiology, prevention, clinical research, and health services research. He initiated the development of several areas of research including national surveys of prevalence of mental disorders, mental health service use in primary care and specialty settings, the organization and financing of such services, and international programs on the classification of mental disorders with the World Health Organization. He served as the Scientific Coordinator/Director for four National Advisory Mental Health Council reports to Congress on mental health insurance parity, and was a section editor of the Surgeon’s General’s Report on Mental Health. In the international arena, Dr. Regier served as the mental health coordinator for the Health Committee of the U.S./Russian Commission on Science and Technology and remains as a consultant to the World Health Organization’s mental health initiatives. He is currently the American Editor for the journal, Social Psychiatry and Psychiatric Epidemiology. He has also published over 150 articles, book chapters, and monographs. He received his medical degree from the Indiana University School of Medicine and completed his medical internship at Montefiore Hospital in the Bronx. After a psychiatry residency at the Massachusetts General Hospital (MGH)/Harvard Medical School, he completed his research training at the Harvard School of Public Health and a fellowship at MGH. At the completion of his NIMH service, Dr. Regier retired as a Rear Admiral and Assistant Surgeon General in the Commissioned Corps of the United States Public Health Service.


Noreen A. Reilly-Harrington, PhD
Director of Training and Assessment
NIMH Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD)
Harvard Medical School, Boston, MA

Noreen Reilly-Harrington, Ph.D. is a Founding Fellow of the Academy of Cognitive Therapy and specializes in the cognitive-behavioral treatment of bipolar disorder. She has co-authored several books and numerous manuscripts on this topic. She is a graduate of the University of Pennsylvania and Temple University and completed both her pre-doctoral internship and post-doctoral fellowship in cognitive-behavioral therapy at Massachusetts General Hospital and Harvard Medical School. Dr. Reilly-Harrington served as the Clinical and Scientific Coordinator of the Psychosocial Pathway in the NIMH Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD), the largest study of bipolar disorder ever conducted. She has also been the Principal Investigator on two NIMH-sponsored Small Business Innovative Research projects geared at improving the design and reliability of multi-site psychiatric assessment and research. Currently, Dr. Reilly-Harrington serves as the Director of Training and Assessment for the NIMH-sponsored Bipolar Trials Network and advises the multi-site network on protocol design, assessment selection, and training. Dr. Reilly-Harrington is also actively involved in the teaching and provision of cognitive-behavioral treatment at the Massachusetts General Hospital Bipolar Clinic and Research Program and is on the faculty of Harvard Medical School. She also serves as an affiliated faculty member for the Career Development Institute for Bipolar Disorder.


Barbara Jacquelyn Sahakian, FMedSci
Professor of Clinical Neuropsychology, University of Cambridge Department of Psychiatry
Behavioural and Clinical Neuroscience Institute, Cambridge, UK

Barbara J Sahakian is Professor of Clinical Neuropsychology at the Department of Psychiatry, University of Cambridge School of Clinical Medicine and Honorary Consultant Clinic Psychologist at Addenbrooke’s Hospital. She has an international reputation in the fields of cognitive psychopharmacology, neuroethics, neuropsychology, neuropsychiatry and neuroimaging. She is co-inventor of the CANTAB computerised neuropsychological tests, which are in use world-wide. She is probably best known for her research work on cognition and depression, cognitive enhancement using pharmacological treatments, neuroethics and early detection of Alzheimer’s disease. Indeed, she has over 300 publications covering these topics in scientific journals, including Science, Nature, Nature Neuroscience, The Lancet, British Medical Journal, Archives of General Psychiatry, American Journal of Psychiatry, Biological Psychiatry, the Journal of Neuroscience, Brain, Psychopharmacology and Psychological Medicine. Her current program of research, funded by the Wellcome Trust and Medical Research Council, investigates the neurochemical modulation of impulsive and compulsive behaviour in neuropsychiatric disorders, such as unipolar and bipolar depression and attention deficit hyperactivity disorder. This topic was the focus of her recent papers published in Science, (Chamberlain et al 2006, Chamberlain et al 2008).

Professor Sahakian was one of the first researchers to suggest that attentional dysfunction in Alzheimer’s disease could be ameliorated using pharmacotherapy, such as cholinesterase inhibitors. In addition, she was early to highlight the cognitive changes in unipolar and bipolar depression, as well as their significance for functional outcome. In 2003, she was selected to lecture on this topic for the Teaching Day at the annual meeting of the American College of Neuropsychopharmacology (ACNP). Most recently, she has introduced the importance of the concept of cognitive reserve to the field of neuropsychiatry (Psychological Medicine, 2006, 36, 1053-1064).

In recognition of her contribution to cognitive neuroscience, she was elected a Fellow of the Academy of Medical Sciences in 2004 and in 2005 she was awarded the Donders Chair in Psychopharmacology at Utrecht University (The Netherlands). In 2008 she gave the Deakin Innovation Lectures in Melbourne, Australia and she was the first woman to give a plenary lecture at ECNP (Barcelona). In 2009 to 2010, she will take up the Distinguished International Scholars Award at the University of Pennsylvania (USA). From November 2005, Dr. Sahakian began a three-year appointment to the Committee of Women in Neuroscience for the Society for Neuroscience (SFN, USA). In 2006 she began her appointment on the Medical Research Council (MRC) Neurosciences and Mental Health Board and in 2008 she was appointed to the MRC Expert Group for Strategy on Mental Health.. Also recently she was appointed to the Executive Committee of the newly formed Neuroethics Society and is on the Editorial Board of the American Journal of Bioethics – Neuroscience. In 2006 she was appointed as a member of the Science Co-ordination Team for the Foresight Project on Mental Capital and Wellbeing (UK Office of Science, Department of Innovation, Universities and Skills). (www.foresight.gov.uk). This project was launched in October 2008 (Beddington et al 2008 Nature).


Trisha Suppes, MD, PhD
Professor of Psychiatry and Behavioral Sciences, Stanford University School of Medicine
Palo Alto Veterans Affairs Medical Center, Palo Alto, CA

Trisha Suppes, M.D., Ph.D. joined the faculty of Stanford University and the VA Palo Alto as Professor of Psychiatry and Behavioral Sciences in 2008, following more than fifteen years at the University of Texas Southwestern Medical Center. Her areas of expertise and research include long-term treatment strategies for bipolar disorder, treatment for bipolar II disorder, development and implementation of treatment algorithms, treatment of bipolar depression and use of complementary medicine for bipolar disorder. A 1987 graduate of Dartmouth Medical School, Dr. Suppes is a member of the American Psychiatric Association (APA) Work Group for the Practice Guidelines for Bipolar Disorder and the Mood Disorder Workgroup for the development of the Diagnostic and Statistical Manual for Mental Disorders, version V. Additionally, Dr. Suppes is an associate editor for the American Journal of Psychiatry and a member of the Scientific Advisory Board of the Depression and Bipolar Support Alliance. She has authored or co-authored over 170 peer-reviewed articles.


Holly A. Swartz, MD
Associate Professor of Psychiatry
University of Pittsburgh School of Medicine
Western Psychiatric Institute and Clinic, Pittsburgh, PA

Dr. Swartz received a bachelor’s degree from Harvard University in Cambridge, Massachusetts and her medical degree from the Albert Einstein College of Medicine in the Bronx, New York. She completed her psychiatric residency at Payne Whitney Clinic-New York Hospital in New York City, and she joined the faculty of the Department of Psychiatry at the University of Pittsburgh Medical School in 1997. She is currently the medical director of the Bipolar Intensive Outpatient Program and attending psychiatrist at the Depression and Manic-Depression Prevention Program of Western Psychiatric Institute and Clinic.

Dr. Swartz’s research is supported by the National Institute of Mental Health (NIMH) and NARSAD and focuses on the development and evaluation of psychosocial interventions for the treatment of mood disorders. She is currently evaluating the roles of psychotherapy and pharmacotherapy in the management of bipolar ll disorder. Dr. Swartz is a prior recipient of a Mentored Patient-Oriented Research Career Development grant from the NIMH. She is the recipient of several research awards including a 2003 NCDEU New Investigator Award, the 2005 Gerald L. Klerman Young Investigator Award from the Depression and Bipolar Support Alliance, and the 2009 Klerman Interpersonal Psychotherapy Award from the International Society for Interpersonal Psychotherapy. She has authored or co-authored over 50 scientific papers and book chapters. Dr. Swartz has presented her work at numerous local, national, and international workshops, conferences and scientific meetings.


Mauricio Tohen, MD, DrPH, MBA
Head of the Division of Mood and Anxiety Disorders
Aaron and Bobbie Eliott Krus Chair Endowed Professor in Psychiatry
University of Texas Health Science Center at San Antonio, TX

Dr. Mauricio Tohen, graduated as a doctor of medicine from the National University of Mexico and as a doctor of public health (epidemiology) from Harvard University. His postdoctoral training included a residency in psychiatry at the University of Toronto and a fellowship at McLean Hospital, Harvard Medical School. He also obtained an MBA degree from Indiana University Kelly School of Business.

From 1988 to 1997, he was clinical director of the Bipolar and Psychotic Disorder Program at McLean Hospital. From 1997 to 2008 he worked at Lilly Research Laboratories attaining the highest possible scientific level of Distinguished Lilly Scholar. In 2009 he joined the University of Texas Health Science Center at San Antonio as Head of the Division of Mood and Anxiety Disorders and the Aaron and Bobbie Eliott Krus Chair Endowed Professor in Psychiatry
He received a National Service Award in Psychiatric Epidemiology from NIMH and Harvard University. He also received a FIRST award from NIMH, the Pope Award from McLean Hospital, and a NARSAD Young Investigator Award.

Dr. Tohen's research, supported by grants from NIMH and the pharmaceutical industry, has focused on the epidemiology, outcome, and treatment of bipolar disorder.

He has served on the Council on Research and the committee on Health Services Research of the American Psychiatric Association. He has also served in the Epidemiology & Genetics and the Clinical Centers and Special Projects Review committees at NIMH. Dr. Tohen has over 200 publications. He has co-edited four books, Psychiatric Epidemiology (1995, second edition 2003), Mood Disorders Across the Life Span (1996) ). Bipolar Disorder: The Upswing In Research and Treatment (2005) and Bipolar Psychopharmacotherapy (2006). He also edited the book Comorbidity in Affective Disorders (1999).


Eduard Vieta, MD, PhD
Professor of Psychiatry
University of Barcelona School of Medicine and
Institute of Clinical Neuroscience, Hospital Clinic
Barcelona, Catalonia, Spain

Eduard Vieta, MD, PhD, is Professor of Psychiatry and Director of the Bipolar Disorders Program of the Hospital Clinic at the University of Barcelona, Barcelona, Spain. He also serves as Director of Research at the Clinical Institute of Neuroscience at the same institution. Professor Vieta’s research focuses on the neurobiology, diagnosis and treatment of bipolar disorder. His program has been at the forefront of research in the area of novel treatments, both pharmacological and psychological, including atypical antipsychotics, antiepileptic drugs, novel compounds, and psychoeducation. Since 2001, his research program has been funded by the Stanley Medical Research Institute, Bethesda, Maryland, USA, and he currently leads the Bipolar Research Program at the Spanish Biomedical Research Network Center on Mental Health (CIBERSAM). His group belongs to the European-Union funded European Network of Bipolar Research Expert Centers (ENBREC). He has made significant contributions to many of the published bipolar disorder treatment guidelines, and has authored more than 300 original articles, 100 book chapters and 25 books on bipolar disorder. He sits on the editorial board of 18 international scientific journals and reviews articles for more than 20 others. Among several international awards, he received the Aristotle award in 2005 and the Mogens Shou award for bipolar disorder research in 2007.


Lakshmi N. Yatham, MBBS, FRCPC, MRCPsych (UK)
Professor of Psychiatry
Associate Head for Research and International Affairs
University of British Columbia in Vancouver, Canada

Lakshmi N. Yatham, MBBS, FRCPC, MRCPsych (UK), is Professor of Psychiatry and Associate Head for Research and International Affairs in the Department of Psychiatry at the University of British Columbia in Vancouver. His major areas of research interest include neurobiology and treatment of bipolar disorder and major depression. Dr. Yatham is a recipient of the Michael Smith Foundation Senior Scholar Award, and his work has been funded by a number of peer-reviewed funding agencies such as the Canadian Institutes of Health Research (CIHR), Canadian Psychiatric Research Foundation, Stanley Foundation, and National Alliance for Research on Schizophrenia and Depression, USA. . Dr. Yatham leads a Canadian consortium on bipolar disorder, which is currently pursuing testing of new treatments for bipolar disorder using pragmatic and controlled trials with substantial funding from CIHR.
Dr. Yatham co-led the development of Canadian guidelines for treatment of bipolar disorder in 1997 and his group recently revised the guidelines for 2005 with International Commentaries, and these are updated and published every 2 years in Bipolar Disorders Journal. He is Chair of the bipolar group of the Canadian Network for Mood and Anxiety Treatments (CANMAT), and is actively involved at a national and international level in continuing medical education and public education on diagnosis and treatment of bipolar disorder for psychiatrists, family physicians, and the general public. Dr. Yatham was the past President of the International Society for Bipolar Disorders. He sits on the editorial boards of a number of journals including Bipolar Disorders, Brain Pharmacology, Human Psychopharmacology, Quarterly Journal of Mental Health etc. He has published over 170 papers in peer-reviewed international journals and presented his research work at numerous international conferences.